在斯里兰卡甘帕哈区评估空间驱避剂(Mosquito Shield™)对≥4-16岁儿童虫媒病毒感染 efficacy 的整群随机安慰剂对照试验:研究方案(AEGIS项目)
本方案拟在斯里兰卡甘帕哈区三个卫生区域开展整群随机、安慰剂对照、双盲临床试验,评估含四氟苯菊酯的空间驱避剂Mosquito Shield™减少儿童虫媒病毒感染的效果。计划从约3900户家庭30个集群中随机选取约14430名≥6月龄者进入发热监测队列,其中约3570名≥4-16岁儿童组成纵向队列,通过基线与随访血清转化及主动疾病监测比较干预与安慰剂集群的差异,并同步开展昆虫学监测。
要点
- 整群随机双盲安慰剂对照设计,30个集群(干预15、安慰剂15)来自约3900户家庭。
- 主要比较纵向队列基线与随访期间登革病毒血清转化率和虫媒病毒病发病率。
- 干预前后及干预期每月监测室内成年埃及伊蚊密度和吸血状态。
核心结论
- 该试验将作为南亚地区空间驱避剂产品的 efficacy 评估,结果将提交世界卫生组织病媒控制咨询组评估公共卫生价值,以支持将空间驱避剂纳入虫媒病毒病控制项目的推荐。
研究设计与样本
- 整群随机、安慰剂对照、双盲临床试验,在斯里兰卡甘帕哈区Negombo、Wattala和Kelaniya三个卫生区域开展。
- 从约3900户家庭30个集群(干预15、安慰剂15)中随机选取约14430名≥6月龄者进入发热监测队列。
- 其中约3570名≥4-16岁、基线采样时血清阴性或仅对既往单一登革病毒血清型感染呈阳性者进入纵向队列,用于基于实验室确认血清转化测量登革病毒感染。
- 基线采样时对多种登革病毒血清型抗体呈阳性者将进行二次分析监测。
- 在干预首次部署(T0)后1-2周内采集纵向队列受试者血清,并在基线采样后约12个月(T1)和约24个月(T2)采集额外样本。
主要发现
- 将比较干预与安慰剂集群之间基线与随访样本的登革病毒血清转化率和虫媒病毒病发病率。
- 参与家庭将在干预部署前3个月内及干预阶段每月接受昆虫学监测,包括室内成年埃及伊蚊种群密度和成年雌蚊吸血状态。
- 将估计并比较各队列登革发病率以确定使用空间驱避剂的公共卫生效益。
- 将测量昆虫学参数以确定是否存在可用于评估新空间驱避剂产品的昆虫学疗效相关指标。
关键数值与推荐
- 纵向队列入组条件为基线采样时≥4-16岁且登革病毒血清阴性或仅单一血清型阳性。
- 血清采样时间点为干预部署后1-2周内(T0)、基线采样后约12个月(T1)和约24个月(T2)。
- 昆虫学监测在干预部署前3个月内及干预阶段每月进行。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Spatial repellents (SRs) have been widely used for prevention of mosquito bites, but their efficacy in reducing Aedes-borne viruses (ABV) has not been tested rigorously at large scale in Asia. To address this knowledge gap, a trial to evaluate the efficacy of Mosquito Shield™, a transfluthrin SR, was developed in Gampaha District of Sri Lanka across three Medical Officer of Health areas; i.e., Negombo, Wattala, and Kelaniya. METHODS: This trial is a cluster-randomized, placebo-controlled, double-blinded clinical trial. A total of ~14,430 subjects aged ≥ 6 months in 30 clusters (15 intervention, 15 placebo) from ~3900 households (HH) will be randomly selected for enrolment into a "febrile surveillance cohort." A subset of the surveillance cohort, ~3570 subjects aged ≥4-16 years that test seronegative (naïve) or are serologically positive for a previous single dengue virus (DENV) infection (monotypic) at baseline sampling, will be enrolled into a "longitudinal cohort" for measuring DENV infection based on laboratory-confirmed seroconversion during the trial. Persons identified positive for antibodies against multiple DENV serotypes (multitypic) at baseline will be monitored for secondary analyses. Active ABV disease will be assessed using an enhanced passive surveillance system with case ascertainment performed in designated healthcare facilities. Serum samples will be taken from longitudinal cohort subjects within 1-2 weeks of when intervention is first deployed (T0) with additional samples taken ~12 (T1) and ~24 months (T2) from baseline sampling. DENV seroconversion and ABV active disease rates from baseline (pre-intervention) and follow-up (post-intervention) samples will be compared between intervention and placebo clusters. Participating houses will be monitored entomologically (indoor adult Aedes aegypti population densities and adult female blood fed status) within 3 months before intervention deployment and monthly during the intervention phase. Entomological surveys will monitor indoor adult Ae. aegypti population densities and blood fed status. Dengue incidence in each cohort will be estimated and compared to determine the public health benefit of using an SR. Entomological parameters will be measured to determine if there are entomological correlates of SR efficacy that may be useful for the evaluation of new SR products. DISCUSSION: The trial will serve as an efficacy assessment of SR products in South Asia. Results will be submitted to the World Health Organization Vector Control Advisory Group for assessment of public health value towards an endorsement to recommend inclusion of SRs in ABV control programs. TRIAL REGISTRATION: Sri Lanka Clinical Trial Registry SLCTR /2022/018. Registered on July 1, 2022. CLINICALTRIALS: gov NCT05452447 . Registered on July 11, 2022. The Universal Trial Number is U1111-1275-3055.
引用
- Tissera H, Dheerasinghe DSAF, Malavige N, et al. A cluster-randomized, placebo-controlled trial to evaluate the efficacy of a spatial repellent (Mosquito Shield™) against Aedes-borne virus infection among children ≥ 4-16 years of age in the Gampaha District, Sri Lanka: study protocol (the AEGIS program). Trials. 2023. PMID: 36600308. doi:10.1186/s13063-022-06998-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。